updat luxturna patient treat
hemophilia data expect
luxturna commerci roll-out track spark provid clariti
patient number lower pt
adjust percentag patient elig luxturna
clinic progress hemophilia program continu investor main
focu manag guid revis protocol unlik near
term updat data hemophilia program expect
remain bullish share see recent weak buy
spark financi upcom mileston
spark maintain strong balanc sheet spark end total cash
includ up-front payment receiv novarti
nv nr januari accord model project
cash runway consist manag guidanc
adjust estim forecast ep vs
previou forecast differ driven ex-u luxturna
deal spark novarti payment specif spark
receiv up-front payment specifi suppli
agreement announc morn project spark would
also receiv mileston payment complet relat
activ payment upon deliveri lastli
believ luxturna approv ema spark receiv
addit payment novarti assum spark like amort
tr target
up-front payment novarti four-year period amort payment
one-year period
adjust pt assum identifi patient elig
treatment tuesday morn earn call manag guid identifi
patient elig luxturna treatment accordingli lower estim
previou adjust result pt averag discount
earn model dcf model clinic npv model
spark stick origin protocol hemophilia program recal share
drop compani announc initi data phase i/ii hemophilia
program american societi hematolog annual meet see investor concern
stem signific variabl factor viii product four patient four week dose
manag note compani plan alter exist trial protocol provid
addit updat addit manag mention hypothet event
higher dose warrant compani need conduct addit preclin
studi given data present far believ biomarin buy edward nash
compar favor regard efficaci model assum
probabl success program maximum market penetr
spark complet ind-en studi spk-gaa pomp diseas pomp
diseas inherit glycogen storag diseas relat defici acid -glucosidas
accord pomp commun current estim incid approxim per
live birth suggest world-wide popul patient approxim peopl
identifi pomp diseas infantil earli onset form juvenil adult
onset form spk-gaa licens genethon privat current standard care pomp
diseas myozym enzym replac therapi market sanofi sni nr accord
evaluatepharma revenu myozym
luxturna commerci roll-out track detail provid spark
final select seven treatment center train surgic arrang among seven
three four center avail launch rest join spark disclos
mani patient identifi elig treatment note three
four-fold increas request gene test kit almost inquiri patient
servic hotlin reimburs front manag state number nation payer
issu draft guidanc line manag expect addit coverag inform
publish addit mani plan accept coverag luxturna case-
by-cas basi compani provid detail regard luxturna roll-out
project spark book approxim peak global sale royalti revenu
page
sale revenu book spark
royalti revenu book spark
acquir in-process research develop
close price
requir disclosur last tab workbook
impair acquir in-process
incom loss oper
total incom expens
incom tax tax benefit
net incom loss tax
net incom loss applic common stockhold
gaap ep basic dilut
weight averag share outstand basic dilut
page
preval mediat retinopathi
number patient mutat
close price
requir disclosur last tab workbook
patient surviv photoreceptor cell benefit gene therapi
total patient elig luxturna treatment
total patient avail luxturna treatment
market penetr luxturna
 patient treat luxturna
treatment luxturna gross-to-net
popul europ mm
preval mediat retinopathi
number patient mutat
patient surviv photoreceptor cell benefit gene therapi
total european patient elig luxturna treatment
total european patient avail luxturna treatment
market penetr luxturna
european patient treat luxturna
treatment luxturna
royalti receiv novarti net sale
luxturna royalti revenu europ mm
popul latin america mm
preval mediat retinopathi
number patient mutat
patient surviv photoreceptor cell benefit gene therapi
total latin american patient elig luxturna treatment
total latin american patient avail luxturna treatment
market penetr luxturna
latin american patient treat luxturna
treatment luxturna
luxturna sale latin america
royalti receiv novarti net sale
luxturna royalti revenu latin america mm
luxturna global sale royalti revenu book spark mm
preval choroideremia
total patient choroideremia
patient surviv photoreceptor cell benefit gene therapi
number choroideremia patient
total number choroideremia patient avail spk-chm treatment
market penetr spk-chm
us choroideremia patient treat withspk-chm
treatment spk-chm
spk-chm sale revenu mm
preval choroideremia
total patient choroideremia
patient surviv photoreceptor cell benefit gene therapi
number choroideremia patient
total number choroideremia patient avail spk-chm treatment
market penetr spk-chm
choroideremia patient treat withspk-chm
treatment spk-chm
preval hemophilia
preval hemophilia
moder sever patient requir treatment
moder sever patient requir treatment
market penetr spk-fix
hemophilia patient treat spk-fix
treatment spk-fix
preval hemophilia
preval hemophilia
moder sever patient requir treatment
moder sever patient requir treatment
market penetr spk-fix
hemophilia patient treat spk-fix
treatment spk-fix
preval hemophilia
moder sever patient requir treatment
moder sever patient requir treatment
market penetr spk-fviii
hemophilia patient treat spk-fviii
treatment spk-fviii
preval hemophilia
moder sever patient requir treatment
moder sever patient requir treatment
market penetr spk-fviii
hemophilia patient treat spk-fviii
treatment spk-fviii
total sale revenu book spark program mm
total royalti revenu book spark program mm
page
spark leverag adeno-associ viru aav technolog develop gene therapi product
treatment genet disord phase pivot studi lead product candid
treatment inherit retin dystrophi ird caus mutat gene met
pre-specifi primari endpoint fda approv luxturna decemb fda
advisori committe vote unanim recommend approv spark novarti enter
agreement novarti commerci luxturna ex-u second program spk-chm
on-going choroideremia anoth genet retin disord addit disord affect
eye spark therapeut pipelin also target liver indic compani
collabor agreement hemophilia phase i/ii clinic trial on-going
hemophilia program continu dose addit cohort improv factor viii level
believ unanim vote fda advisori committe underli strong efficaci
safeti profil luxturna demonstr date expect gradual uptak luxturna
model luxturna target ww commerci opportun believ spk-chm
benefit luxturna clinic success spark expertis deep understand
hemophilia help differenti compani competitor addit spark current
conduct phase i/ii trial hemophilia bring spk-gaa clinic
valuat risk
valuat price target deriv take averag three differ valuat
methodolog pe discount rate use discount earn model
clinic npv model discount rate perpetu growth use
dcf model consist across small-cap compani coverag univers valuat
suggest spark share under-valued current level expect data higher
dose cohort hemophilia program posit could gener strong tailwind stock
risk risk rate price target spark earli stage
biotechnolog compani clinic risk encompass failur product
candid test success complet clinic develop regulatori risk
wherebi approv given delay regulatori agenc number reason final
financi risk enough fund complet clinic develop approv
alway commerci risk associ launch
compani mention note
edward nash herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
